M MYELOID EXTENDED
JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1, CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS, RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53
Myeloproliferative neoplasms, MDS/MPN overlap disorders
Extended myeloid mutation analysis using Illumina TruSight Myeloid Panel targeted resequencing to assess for clinically relevant mutations in the following genes: JAK2 (V617F and Exon 12), CALR (Type 1 and 2), MPL, ASXL1, CBL, CSF3R, ETV6/TEL, EZH2, IDH1, IDH2, KIT, KRAS, NRAS, RUNX1, SETB1, SF3B1, SRSF2, TET2, TP53
10 days
5.0 mL (min. 1.0 mL) whole blood EDTA preferred, heparin whole blood accepted
3.0 mL (min. 1.0 mL) bone marrow aspirate EDTA preferred, heparin accepted
Whole blood and bone marrow ship in a Styrofoam container with a cool pack. (Do not allow cool/refrigerated pack to directly contact sample
Insufficient DNA content; Insufficient specimen volume; Specimen at incorrect temperature; Incorrect anticoagulant
This assay is limited to the detection of SNVs and small to mid-size insertion/deletions (<100 bp) in genes targeted by this panel. The assay does not detect whole gene or exon insertion and deletions, copy number variants or gene rearrangements (fusions). The potential for false negatives for genetic mutations increases in samples with <10% disease type cellularity.
illumina and TruSight are trademarks of illumina Inc,